Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Benefits of minimizing immunosuppressive dosage according to cytochrome P450 3A5 genotype in liver transplant patients: findings from a single-center study.

Genetics and molecular research : GMR - 10 Apr 2015

Wang L, Li N, Wang M X, Lu S C

Abstract excerpt

We evaluated the clinical efficacy of tailoring tacrolimus dosage to cytochrome P450 (CYP) 3A5 genotype in liver transplant patients. One hundred patients who received tacrolimus-based therapy were included in the retrospective study in which the relationship between the tacrolimus blood trough concentration/dosage ratio and the CYP3A5 genotype of both donors and recipients was determined. Subsequently, 106...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytochrome P-450 CYP3A
Share to Graft Rejection

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hyperglycemia

Share to Kidney Diseases

Share to Liver Transplantation

Share to Outcome Assessment, Health Care

Share to Tacrolimus

Share to Tissue Donors

Source

Identifiers

PMID: 25966085
DOI: 10.4238/2015.April.10.31

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Benefits of minimizing immunosuppressive dosage according to cytochrome P450 3A5 genotype in liver transplant patients: findings from a single-center study.PMID 25966085Read ↗

Value of CYP3A5 genotyping on determining initial dosages of tacrolimus for Chinese renal transplant recipients.Semantic proximity Read ↗

Effect of CYP3A5 genotype on renal allograft recipients treated with tacrolimus.Semantic proximity Read ↗

Donor and recipient P450 gene polymorphisms influence individual pharmacological effects of tacrolimus in Chinese liver transplantation patients.Semantic proximity Read ↗

Dosing tacrolimus based on CYP3A5 genotype: will it improve clinical outcome?Semantic proximity Read ↗

Individualization of tacrolimus dosage basing on cytochrome P450 3A5 polymorphism--a prospective, randomized, controlled study.Semantic proximity Read ↗

Clinical Impact of the Adaptation of Initial Tacrolimus Dosing to the CYP3A5 Genotype After Kidney Transplantation: Systematic Review and Meta-Analysis of Randomized Controlled Trials.Semantic proximity Read ↗

Effect of CYP3A5 gene polymorphisms on tacrolimus concentration/dosage ratio in adult liver transplant patients.Semantic proximity Read ↗

Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation.Semantic proximity Read ↗

The importance of MDR1 gene polymorphisms for tacrolimus dosage.Semantic proximity Read ↗

Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients.Semantic proximity Read ↗

Pharmacogenetics of tacrolimus after renal transplantation: analysis of polymorphisms in genes encoding 16 drug metabolizing enzymes.Semantic proximity Read ↗

Tacrolimus dosing in Chinese renal transplant recipients: a population-based pharmacogenetics study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.